FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2537578849> ?p ?o ?g. }

• W2537578849 abstract "Mammalian target of rapamycin (mTOR) represents a key downstream intermediate for a myriad of oncogenic receptor tyrosine kinases. In the case of the insulin-like growth factor (IGF) pathway, the mTOR complex (mTORC1) mediates IGF-1 receptor (IGF-1R)-induced estrogen receptor alpha (ERα) phosphorylation/activation and leads to increased proliferation and growth in breast cancer cells. As a result, the prevalence of mTOR inhibitors combined with hormonal therapy has increased in recent years. Conversely, activated mTORC1 provides negative feedback regulation of IGF signaling via insulin receptor substrate (IRS)-1/2 serine phosphorylation and subsequent proteasomal degradation. Thus, the IGF pathway may provide escape (e.g. de novo or acquired resistance) from mTORC1 inhibitors. It is therefore plausible that combined inhibition of mTORC1 and IGF-1R for select subsets of ER-positive breast cancer patients presents as a viable therapeutic option. Using hormone-sensitive breast cancer cells stably transfected with the aromatase gene (MCF-7/AC-1), works presented herein describe the in vitro and in vivo antitumor efficacy of the following compounds: dalotuzumab (DALO; “MK-0646”; anti-IGF-1R antibody), ridaforolimus (RIDA; “MK-8669”; mTORC1 small molecule inhibitor) and letrozole (“LET”, aromatase inhibitor). With the exception of MK-0646, all single agent and combination treatment arms effectively inhibited xenograft tumor growth, albeit to varying degrees. Correlative tissue analyses revealed MK-0646 alone and in combination with LET induced insulin receptor alpha A (InsR-A) isoform upregulation (both mRNA and protein expression), thereby further supporting a triple therapy approach. These data provide preclinical rationalization towards the combined triple therapy of LET plus MK-0646 plus MK-8669 as an efficacious anti-tumor strategy for ER-positive breast tumors." @default.
• W2537578849 created "2016-10-28" @default.
• W2537578849 creator A5013513429 @default.
• W2537578849 creator A5042220379 @default.
• W2537578849 creator A5042837295 @default.
• W2537578849 creator A5074516218 @default.
• W2537578849 creator A5078233770 @default.
• W2537578849 creator A5079091280 @default.
• W2537578849 creator A5088406750 @default.
• W2537578849 creator A5089153267 @default.
• W2537578849 date "2016-10-20" @default.
• W2537578849 modified "2023-10-17" @default.
• W2537578849 title "Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer" @default.
• W2537578849 cites W1967727813 @default.
• W2537578849 cites W1967899512 @default.
• W2537578849 cites W1976250589 @default.
• W2537578849 cites W1977424304 @default.
• W2537578849 cites W1987117563 @default.
• W2537578849 cites W1997961187 @default.
• W2537578849 cites W2005890897 @default.
• W2537578849 cites W2020617101 @default.
• W2537578849 cites W2027326117 @default.
• W2537578849 cites W2040104879 @default.
• W2537578849 cites W2061477949 @default.
• W2537578849 cites W2077945404 @default.
• W2537578849 cites W2078515109 @default.
• W2537578849 cites W2096655031 @default.
• W2537578849 cites W2099063182 @default.
• W2537578849 cites W2110189733 @default.
• W2537578849 cites W2113761994 @default.
• W2537578849 cites W2125200558 @default.
• W2537578849 cites W2126783165 @default.
• W2537578849 cites W2129099267 @default.
• W2537578849 cites W2129938104 @default.
• W2537578849 cites W2130642180 @default.
• W2537578849 cites W2131058993 @default.
• W2537578849 cites W2131100943 @default.
• W2537578849 cites W2154546161 @default.
• W2537578849 cites W2157983986 @default.
• W2537578849 cites W2319017688 @default.
• W2537578849 cites W2414818283 @default.
• W2537578849 doi "https://doi.org/10.1186/s12885-016-2847-3" @default.
• W2537578849 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5073873" @default.
• W2537578849 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27765027" @default.
• W2537578849 hasPublicationYear "2016" @default.
• W2537578849 type Work @default.
• W2537578849 sameAs 2537578849 @default.
• W2537578849 citedByCount "8" @default.
• W2537578849 countsByYear W25375788492017 @default.
• W2537578849 countsByYear W25375788492018 @default.
• W2537578849 countsByYear W25375788492019 @default.
• W2537578849 crossrefType "journal-article" @default.
• W2537578849 hasAuthorship W2537578849A5013513429 @default.
• W2537578849 hasAuthorship W2537578849A5042220379 @default.
• W2537578849 hasAuthorship W2537578849A5042837295 @default.
• W2537578849 hasAuthorship W2537578849A5074516218 @default.
• W2537578849 hasAuthorship W2537578849A5078233770 @default.
• W2537578849 hasAuthorship W2537578849A5079091280 @default.
• W2537578849 hasAuthorship W2537578849A5088406750 @default.
• W2537578849 hasAuthorship W2537578849A5089153267 @default.
• W2537578849 hasBestOaLocation W25375788491 @default.
• W2537578849 hasConcept C121608353 @default.
• W2537578849 hasConcept C126322002 @default.
• W2537578849 hasConcept C172313692 @default.
• W2537578849 hasConcept C185592680 @default.
• W2537578849 hasConcept C502942594 @default.
• W2537578849 hasConcept C530470458 @default.
• W2537578849 hasConcept C62478195 @default.
• W2537578849 hasConcept C71924100 @default.
• W2537578849 hasConcept C84606932 @default.
• W2537578849 hasConcept C86554907 @default.
• W2537578849 hasConcept C86803240 @default.
• W2537578849 hasConcept C95444343 @default.
• W2537578849 hasConcept C98490376 @default.
• W2537578849 hasConceptScore W2537578849C121608353 @default.
• W2537578849 hasConceptScore W2537578849C126322002 @default.
• W2537578849 hasConceptScore W2537578849C172313692 @default.
• W2537578849 hasConceptScore W2537578849C185592680 @default.
• W2537578849 hasConceptScore W2537578849C502942594 @default.
• W2537578849 hasConceptScore W2537578849C530470458 @default.
• W2537578849 hasConceptScore W2537578849C62478195 @default.
• W2537578849 hasConceptScore W2537578849C71924100 @default.
• W2537578849 hasConceptScore W2537578849C84606932 @default.
• W2537578849 hasConceptScore W2537578849C86554907 @default.
• W2537578849 hasConceptScore W2537578849C86803240 @default.
• W2537578849 hasConceptScore W2537578849C95444343 @default.
• W2537578849 hasConceptScore W2537578849C98490376 @default.
• W2537578849 hasIssue "1" @default.
• W2537578849 hasLocation W25375788491 @default.
• W2537578849 hasLocation W25375788492 @default.
• W2537578849 hasLocation W25375788493 @default.
• W2537578849 hasLocation W25375788494 @default.
• W2537578849 hasOpenAccess W2537578849 @default.
• W2537578849 hasPrimaryLocation W25375788491 @default.
• W2537578849 hasRelatedWork W1488655057 @default.
• W2537578849 hasRelatedWork W2025935112 @default.
• W2537578849 hasRelatedWork W2054117275 @default.
• W2537578849 hasRelatedWork W2076822465 @default.
• W2537578849 hasRelatedWork W2157618662 @default.
• W2537578849 hasRelatedWork W2342462201 @default.

• next